FDA approves Leo Pharma's tralokinumab after rejection 8 months ago
Eight months after Leo Pharma's atopic eczema treatment, tralokinumab, was rejected in the US, the FDA gives the Danish firm's drug the thumbs-up. Leo Pharma can now market and sell the drug in the US, which could double the company's size, says Leo Pharma executive Becki Morison.
by ULRICH QUISTGAARD, translated by daniel pedersen
The US Food and Drug Administration (FDA) approves of Leo Pharma's biologic drug, tralokinumab, against atopic eczema in adults, Leo Pharma announce in a press release.